Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

ClinicalTrials.gov ID: NCT00085644

Public ClinicalTrials.gov record NCT00085644. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are intolerant to, treatment with at least 1 nonsteroidal anti-inflammatory drug (NSAID) and who may have also failed treatment with at least 1 disease-modifying antirheumatic drug (DMARD).

Study identification

NCT ID: NCT00085644
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Abbott; Industry
Enrollment: 315 participants

Conditions and interventions

Conditions

Ankylosing Spondylitis

Interventions

adalimumab (D2E7) Biological
placebo Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2004 (Type not available)
Primary completion: Dec 2004 (Actual)
Completion: Jul 2009 (Actual)
Last update posted: Apr 21, 2011

2004 – 2009

United States locations

U.S. sites: 22
U.S. states: 16
U.S. cities: 21

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35924	—
Not listed	Mobile	Alabama	36608	—
Not listed	San Francisco	California	94143	—
Not listed	Colorado Springs	Colorado	80910	—
Not listed	Denver	Colorado	80230	—
Not listed	Boise	Idaho	83706	—
Not listed	Chicago	Illinois	60611	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Portland	Maine	04102	—
Not listed	Baltimore	Maryland	21224	—
Not listed	Wheaton	Maryland	20902	—
Not listed	Omaha	Nebraska	68114	—
Not listed	Lebanon	New Hampshire	03756	—
Not listed	Albany	New York	12206	—
Not listed	Oklahoma City	Oklahoma	73112	—
Not listed	Duncansville	Pennsylvania	16635	—
Not listed	West Reading	Pennsylvania	19611	—
Not listed	Dallas	Texas	75231	—
Not listed	Houston	Texas	77030	—
Not listed	Houston	Texas	77074	—
Not listed	Salt Lake City	Utah	84132	—
Not listed	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00085644, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 21, 2011 · Synced Oct 29, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00085644 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →